Real-world use of insulin degludec/liraglutide (IDegLira) significantly improves glycaemic control in patients with Type 2 diabetes

被引：0
|
作者：
Feher, M. [1 ]
Price, H. [2 ]
Schultes, B. [3 ]
Prager, R. [4 ]
Phan, T. M. [5 ]
Thorsted, B. L. [6 ]
Bluher, M. [7 ]
机构：
[1] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[2] Southern Hlth NHS Fdn Trust, Bournemouth, Dorset, England
[3] ESwiss Med & Surg Ctr, Internal Med, St Gallen, Switzerland
[4] Hietzing Hosp, Dept Metab Disorders & Nephrol, Vienna, Austria
[5] Novo Nordisk Reg Europe Pharmaceut AS, Copenhagen, Denmark
[6] Novo Nordisk AS, Global Market Access, Soborg, Denmark
[7] Univ Leipzig, Dept Med, Leipzig, Germany
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P391
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [1] Switching to insulin degludec (IDeg) improves glycaemic control in patients with Type 2 diabetes in a real-world setting
    Feher, M.
    Tentolouris, N.
    Knudsen, S.
    Lapolla, A.
    Prager, R.
    Phan, T. M.
    Wolden, M. L.
    Schultes, B.
    [J]. DIABETIC MEDICINE, 2018, 35 : 203 - 203
  • [2] Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
    Gough, Stephen C. L.
    Jain, Rajeev
    Woo, Vincent C.
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (01) : 7 - 19
  • [3] Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin
    Kumar, S.
    Aroda, V.
    Bailey, T.
    Cariou, B.
    Leiter, L.
    Raskin, P.
    Zacho, J.
    Philis-Tsimikas, A.
    [J]. DIABETIC MEDICINE, 2015, 32 : 66 - 66
  • [4] Real-World Use of IDegLira Significantly Improves Glycemic Control in Patients with T2D
    Price, Hermione
    Schultes, Bernd
    Prager, Rudolf
    Tra Mi Phan
    Thorsted, Brian L.
    Bluher, Matthias
    [J]. DIABETES, 2017, 66 : A257 - A257
  • [5] Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
    Meneghini, L.
    Doshi, A.
    Gouet, D.
    Vilsboll, T.
    Begtrup, K.
    Orsy, P.
    Ranthe, M. F.
    Lingvay, I.
    [J]. DIABETIC MEDICINE, 2020, 37 (02) : 267 - 276
  • [6] Patients with type 2 diabetes on the maximum dose of insulin degludec/liraglutide (IDegLira) achieve glycaemic target: analyses from the DUAL programme
    Meneghini, L.
    Linjawi, S.
    Serusclat, P.
    Vilsboll, T.
    Agner, B. F.
    Hansen, T.
    Leiter, L. A.
    [J]. DIABETOLOGIA, 2018, 61 : S413 - S413
  • [7] In patients with Type 2 diabetes, treatment with IDegLira, a combination of insulin degludec and liraglutide, improves both preprandial and postprandial plasma glucose
    Viljoen, A.
    King, A.
    Philis-Tsimikas, A.
    Langbakke, I. H.
    Kvist, K.
    Vilsboll, T.
    [J]. DIABETIC MEDICINE, 2015, 32 : 74 - 74
  • [8] INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE
    Al Awadi, F.
    Aly, H.
    Bashier, A.
    Benavente, J. Medina
    Dhanwal, D. Kumar
    Jallo, M.
    Singhal, S.
    Abusnana, S.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [9] IDegLira, a combination of insulin degludec and liraglutide, improves both pre- and postprandial plasma glucose in patients with type 2 diabetes
    King, A.
    Philis-Tsimikas, A.
    Langbakke, I. H.
    Kvist, K.
    Vilsboll, T.
    [J]. DIABETOLOGIA, 2014, 57 : S108 - S109
  • [10] IDegLira, a combination of insulin degludec and liraglutide, enables patients with type 2 diabetes to reach target glycaemic control faster than its individual components alone
    Vilsboll, T.
    Vora, J.
    Jarlov, H.
    Kvist, K.
    Blonde, L.
    [J]. DIABETOLOGIA, 2014, 57 : S339 - S339
12345